Ilah Bok

This study identifies MAFG as a driver of melanoma progression by interacting with MITF to alter gene expression and promote a dedifferentiated melanoma phenotype.

This paper introduces VVD-065, a covalent NRF2 inhibitor that enhances NRF2 degradation and sensitizes tumors to therapy, supporting a Phase I clinical trial.

This paper develops genetic tools for stable circRNA overexpression in vitro and in vivo, demonstrating their utility in cell culture and mouse models.